Fosun Pharma (02196) announced that its controlling subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd., has recently launched a Phase II clinical trial in China for FXR0906 injection for the treatment of hypertriglyceridemia.